Last reviewed · How we verify

C.B. Fleet Company, Inc. — Portfolio Competitive Intelligence Brief

C.B. Fleet Company, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahmed M Maged, MD · 1 shared drug class
  2. Amsterdam UMC, location VUmc · 1 shared drug class
  3. Azienda Policlinico Umberto I · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Benaroya Research Institute · 1 shared drug class
  6. Bo-In Lee · 1 shared drug class
  7. Braintree Laboratories · 1 shared drug class
  8. Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for C.B. Fleet Company, Inc.:

Cite this brief

Drug Landscape (2026). C.B. Fleet Company, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/c-b-fleet-company-inc. Accessed 2026-05-17.

Related